Vaccine by Nov. 3? Halted study explains just how unlikely
Share
Tweet
September 9, 2020
WASHINGTON (AP) — The suspension of a huge COVID-19 vaccine study over an illness in a single participant shows there will be "no compromises" on safety in the race to develop the shot, the chief of the National Institutes of Health told Congress on Wednesday.
AstraZeneca has put on hold studies of its vaccine candidate in the U.S. and other countries while it investigates whether a British volunteer's illness is a side effect or a coincidence.
"This ought to be reassuring," NIH Director Dr. Francis Collins said before a Senate committee. "When we say we are going to focus first on safety and...
For access to this article please
sign in or
subscribe.
Reader Comments(0)